Donate Today!
COMAPC News
Beards of Science Makes Donation to COMAPC

Michael D. Hughes, COMAPC President, received a $4,000 donation to COMAPC from the Beards of Science.  COMAPC will use the donation to increase its funding for screenings for uninsured and underserved men and expand its education and outreach programs in Central Ohio. Click here to read more about the Beards of Science.

Congressionally Directed Medical Research Programs - Department of Defense

2011 Innovative Minds in Prostate Cancer Today (IMPaCT)

Egbert C. (Bert) Brown, Board Secretary, represented Central Ohio Men Against Prostate Cancer at the 2011 Innovative Minds in Prostate Cancer Today (IMPaCT) Conference in Orlando, Florida.  Brown, a 14 year prostate cancer survivor, was invited to attend because of his prior participation as a consumer reviewer for the Department of Defense Prostate Cancer Research Program.  In addition, Brown delivered the opening session moment of silence.  Click here to view Brown’s introduction and presentation.

  Prostate Cancer Research Program

Egbert C. (Bert) Brown, board secretary for Central Ohio Men Against Prostate Cancer, was selected by the U.S. Army Medical Research and Materiel Command (USAMRMC) Department of Defense Prostate Cancer Research Program (PCRP), to participate as a consumer advocate reviewer.  This is the fourth year that Brown has been chosen and he worked as a full voting member with prominent scientists to help determine how the $80 million appropriated by Congress for Fiscal Year 2011 (FY11) will be spent on future prostate cancer research.  Click here to read more about the PCRP.


Breaking News
Victory for Men's Health; Medicare Will Keep Covering Prostate Cancer Screening

After Congressmen Dennis Kucinich (D-OH), Dan Burton (R-IN) and Don Young (R-AK) organized a bipartisan group of 44 Members of Congress to object to a recommendation by the United States Preventative Task Force (USPTF) that healthy men should not receive a blood test to screen for prostate cancer, Health and Human Services Secretary Kathleen Sibelius agreed to overrule the recommendation.  Click here to read more.

UNC scientists collaborate to find first major genetic mutation associated with hereditary prostate cancer risk

After a 20-year quest, researchers have identified a rare, inherited mutation linked to a significantly higher risk of the disease.  Click here to read more.

Prostate Cancer Research News
Pelotonia To Fund Additional Cancer Research At Ohio State

Six teams of scientists at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute are each receiving two-year, $100,000 Pelotonia Research Awards to fund “high-risk, high-reward” research projects involving blood, breast, liver, prostate and skin cancers.  Click here to read more.

A New Study Suggests That A Neurotransmitter Might Improve The Treatment Of Cancer

Doses of a neurotransmitter might offer a way to boost the effectiveness of anticancer drugs and radiation therapy, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.  Click here to read more.


Prostate Cancer Treatment News
Abiraterone Improves Survival in Metastatic Prostate Cancer

A multinational phase III trial found that the drug abiraterone acetate prolonged the median survival time of patients with metastatic castration-resistant prostate cancer by 4 months compared with patients who received a placebo.  Click here to read more.

NIH-funded study shows reduction in death for men with intermediate-grade prostate cancer: (NCI Press Release)

Short-term hormone therapy given in combination with radiation therapy to men with early-stage prostate cancer increased their chances of living longer compared to treatment with radiation therapy alone... Click here to read more.

Xgeva Delays Bone Metastases from Prostate Cancer

Among men with prostate cancer that has stopped responding to hormonal therapy, the bone drug Xgeva (denosumab) delayed the spread of cancer to the bones. These results were recently published in The Lancet, and were previously presented at the 2011 European Multidisciplinary Cancer Conference.  Click here to read more.

Disclaimer: The content presented on our website (www.comapc.org) is provided solely for informational purposes.  News articles on this page do not necessarily reflect the opinions of COMAPC or any of its members.  None of this information should be used as a substitute for professional medical advice.  Please consult with your personal physician for medical advice.